|
佐藤 加代子
Department School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine Position |
|
| Article types | Original article |
| Language | English |
| Peer review | Peer reviewed |
| Title | Statement for Appropriate Clinical Use of PCSK9 Inhibitors. |
| Journal | Formal name：Journal of atherosclerosis and thrombosis Abbreviation：J Atheroscler Thromb ISSN code：1340-3478/1880-3873 |
| Domestic / Foregin | Domestic |
| Publisher | Japan Atherosclerosis Society |
| Volume, Issue, Page | 25(8),pp.747-750 |
| Author and coauthor | Nohara Atsushi, Ohmura Hirotoshi, Okazaki Hiroaki, Ogura Masatsune, Kitagawa Kazuo, Koseki Masahiro, Sato Kayoko, Tsukamoto Kazuhisa, Yamashita Shizuya, On behalf of the Japan Atherosclerosis Society Working Group on Statement for Appropriate Use of PCSK9 Inhibitors |
| Publication date | 2018/08 |
| Summary | PCSK9 inhibitors should be used for secondary prevention in patients with coronary artery disease when LDL-C management targets are not achieved with treatment combining ezetimibe and statins at the maximum tolerated dose, who include many FH heterozygotes. We have described the types of patients who would receive great benefit from PCSK9 inhibitors from the viewpoints of medical and medical economics at the present time and provided flowcharts for LDL-C lowering therapy including PCSK9 inhibitors. In initiating or continuing PCSK9 inhibitors, attention should be paid to the latest information and an experienced specialist should be consulted when necessary. |
| DOI | 10.5551/jat.45229 |
| PMID | 29899173 |